Browse by People


Up a level
Export as [feed] RSS [feed] RSS 2.0 Short Author List
Number of items: 4.


Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Hoppe, Anne, Ndashimye, Emmanuel, Warambwa, Colin, Mambule, Ivan, van Oosterhout, Joep J, Wools-Kaloustian, Kara, Bertagnolio, Silvia
et al (show 4 more authors) (2017) HIV Drug Resistance Mutations in Non-B Subtypes After Prolonged Virological Failure on NNRTI-Based First-Line Regimens in Sub-Saharan Africa. JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 75 (2). E45-E54.


Hakim, James G, Thompson, Jennifer, Kityo, Cissy, Hoppe, Anne, Kambugu, Andrew, van Oosterhout, Joep J, Lugemwa, Abbas, Siika, Abraham, Mwebaze, Raymond, Mweemba, Aggrey
et al (show 7 more authors) (2017) Lopinavir plus nucleoside reverse-transcriptase inhibitors, lopinavir plus raltegravir, or lopinavir monotherapy for second-line treatment of HIV (EARNEST): 144-week follow-up results from a randomised controlled trial. The Lancet. Infectious diseases, 18 (1). pp. 47-57.


Shi, Yuan, Thompson, Jennifer, Walker, A Sarah, Paton, Nicholas I, Cheung, Yin Bun, Agweng, E, Awio, P, Bakeinyaga, G, Isabirye, C, Kabuga, U
et al (show 272 more authors) (2019) Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3L) utility index. HEALTH AND QUALITY OF LIFE OUTCOMES, 17 (1). 83-.


Paton, Nicholas I, Kityo, Cissy, Thompson, Jennifer, Nankya, Immaculate, Bagenda, Leonard, Hoppe, Anne, Hakim, James, Kambugu, Andrew, van Oosterhout, Joep J, Kiconco, Mary
et al (show 5 more authors) (2017) Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial. The lancet. HIV, 4 (8). e341-e348.

This list was generated on Sun Mar 24 03:51:34 2024 GMT.